GAITHERSBURG, Md.--(BUSINESS WIRE)--Bridge Laboratories announced today that the FDA has accepted data submitted from its Beijing facility on behalf of a US biotech client. The Good Laboratory Practices (GLP) nonhuman primate toxicology study data was generated and submitted last month as part of an IND package to the FDA. Bridge’s Beijing facility was purpose built to conduct GLP studies in support of worldwide regulatory submission – this goal has now been fully realized.
